Ebb & Flow

Not only does Tularik's collaboration with Amgen provide funding and a seal of approval for TLRK's cancer platform, it also provides a smooth exit for a major investor - ZKB Pharma Vision - and removes the significant overhang of stock that ZKB was planning to sell.

ZKB, an early investor in TLRK, in January registered 11.4 million shares (21% of total shares outstanding), putting significant pressure on the stock (see BioCentury, Feb. 3). But now AMGN will purchase the ZKB shares for an undisclosed price as part of last week's multi-faceted deal...